Head-To-Head Contrast: Centessa Pharmaceuticals (NASDAQ:CNTA) versus Pivotal Therapeutics (OTCMKTS:PVTTF)

Centessa Pharmaceuticals (NASDAQ:CNTA) and Pivotal Therapeutics (OTCMKTS:PVTTF) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, profitability, valuation and risk.

Institutional and Insider Ownership

82.0% of Centessa Pharmaceuticals shares are owned by institutional investors. 4.1% of Centessa Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Centessa Pharmaceuticals and Pivotal Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Centessa Pharmaceuticals	N/A	N/A	-$197.53 million	($1.79)	-22.63
Pivotal Therapeutics	N/A	N/A	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of current ratings and target prices for Centessa Pharmaceuticals and Pivotal Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Centessa Pharmaceuticals	1	9	4	0	2.21
Pivotal Therapeutics	0	0	0	0	0.00

Centessa Pharmaceuticals currently has a consensus target price of $41.33, indicating a potential upside of 2.06%. Given Centessa Pharmaceuticals’ stronger consensus rating and higher probable upside, research analysts plainly believe Centessa Pharmaceuticals is more favorable than Pivotal Therapeutics.

Risk and Volatility

Centessa Pharmaceuticals has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500. Comparatively, Pivotal Therapeutics has a beta of 1.48, meaning that its share price is 48% more volatile than the S&P 500.

Profitability

This table compares Centessa Pharmaceuticals and Pivotal Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Centessa Pharmaceuticals	N/A	-60.37%	-44.17%
Pivotal Therapeutics	N/A	N/A	N/A

Summary

Centessa Pharmaceuticals beats Pivotal Therapeutics on 5 of the 8 factors compared between the two stocks.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

About Pivotal Therapeutics

Pivotal Therapeutics Inc., a specialty pharmaceutical company, focuses on the treatment of cardiovascular diseases and overall health. Its lead product, VASCAZEN, is a prescription only medical food formulated for clinical dietary management of cardiovascular disease in patients with documented coronary heart disease and who are deficient in blood Omega-3 fatty acids, eicosapentaenoic acid, and docosahexanenoic acid levels. The company also offers OMAZEN for the maintenance of good health through elevating Omega-3 fatty acid levels. In addition, the company develops Benefishial product line for overall health, cardiovascular health, prenatal health, toddler’s health, child’s health, and pet’s health. Further, it is developing PVT-100 indicated for the stabilization of vulnerable plaque in patients undergoing carotid endarterectomy. Pivotal Therapeutics Inc. sells VASCAZEN in the United States and OMAZEN in Canada. The company is headquartered in Woodbridge, Canada.